免疫抑制持续的异种移植接受需要PD1抑制CD8+T细胞
Hilary Miller-Handley1,2, Gavin Harper1, Giang Pham1
1Division of Infectious Diseases, Center for Inflammation and Tolerance, Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Journal of immunology (Baltimore, Md. : 1950)
|March 12, 2025
概括
器官移植接受者需要免疫抑制药物来防止排斥. 这项研究表明,抑制PD1通路对于维持小鼠接受皮肤全移植至关重要,这解释了PD1/PDL1疗法为什么会导致移植排斥.
科学领域:
- 免疫学 免疫学 免疫学
- 移植生物学 移植生物学
- T细胞生物学T细胞生物学
背景情况:
- 器官移植接受者需要终身免疫抑制以防止排斥.
- 药物不服药是移植排斥的主要原因,但潜在的机制尚不清楚.
- 了解免疫耐受机制对于改善移植结果至关重要.
研究的目的:
- 在小鼠中研究药物停用后的异种移植排斥的机制.
- 阐明PD1信号传递在器官移植后维持免疫耐受性的作用.
- 探索免疫抑制疗法,T细胞功能和异种移植接受之间的联系.
主要方法:
- 使用鼠标皮肤全移植模型与塔克罗利和酸免疫抑制.
- 分析了特定于移植的CD8+T细胞表型和功能,包括PD1表达.
- 研究了PDL1阻断对异体移植排斥的作用,尽管正在进行免疫抑制.
主要成果:
- 免疫抑制疗法使移植特异性CD8+T细胞敏感,其特征是PD1表达增加和效应器功能降低.
- 停止使用免疫抑制药物导致异种移植的排斥.
- 阻断PDL1逆转T细胞抑制并导致排斥,即使持续免疫抑制.
结论:
- 通过PD1介导的CD8+T细胞的抑制对于维持在塔克罗利和mycophenolate疗法下的全移植接受是必不可少的.
- 这种PD1依赖性解释了为什么接受PD1/PDL1抑制剂的癌症患者体验到更高的移植排斥率.
- 共享的免疫抑制途径被瘤和移植耐受性策略都利用.
更多相关视频
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
14.5K
08:41Functional Characterization of Regulatory Macrophages That Inhibit Graft-reactive Immunity
Published on: June 7, 2017
8.2K
相关概念视频
01:40Cell-mediated Immune Responses
66.6K
Overview
66.6K
01:27Tumor Immunotherapy
457
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
457